Aerovate Therapeutics Teams with Westwood & Wilshire to Place Senior Vice President of Clinical Development

This article was originally posted on Linkedin

Dr. Cheryl Lassen has joined the Aerovate team of experts as Senior Vice President of Clinical Development. Cheryl brings extensive knowledge of PAH and PH clinical trials, having worked for more than 30 years as a leader in clinical development and medical affairs for related clinical research programs for several pharmaceutical companies. As a trailblazer in treatment for PH, she oversaw the regulatory filings of the first FDC and comes to Aerovate with a wide range of experience across companies in the field of respiratory disease. Cheryl's deep expertise further enhances Aerovate’s multidisciplinary team of accomplished PAH veterans. As the newest member of our driven group, she will focus on our IMPAHCT study and advancing AV-101, our novel dry powder inhaled formulation of the drug imatinib.

The search was successfully led by Gerard Danishek.

About Aerovate Therapeutics

Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.

About Westwood & Wilshire

Westwood & Wilshire is a retained executive-search firm delivering premier talent in life sciences, healthcare and advanced technology to the world’s most innovative companies. Our specialty is bringing top-flight senior leadership to growing venture-backed companies looking for the best people to fill their C-Suite hires. Clients around the globe work with Westwood & Wilshire to build world-changing companies. Contact information can be found at https://westwoodwilshire.com/contact-us.